Happy Birthday Roengten-27th March
Wilhelm Conrad Röentgen ( 27 March 1845 – 10 February 1923) was a German physicist, who, on 8 November 1895, produced and detected electromagnetic radiation in a wavelength range today known as X-rays or Röentgen rays, an achievement that earned him the first Nobel Prize in Physics in 1901. Röentgen died on 10 February 1923 from carcinoma of the intestine. Röentgen did not take patents out on his discoveries, and donated the money for his Nobel prize to the University of Würzburg. Great man indeed!!
Also today is Holi- Indian festival of colors-Wishing you all and your families a very bright,colourful and joyf...
Source: Sumer's Radiology Site - March 27, 2013 Category: Radiologists Authors: Sumer Sethi Source Type: blogs
Breast Cancer
Pathophysiology of Breast Cancer
Breast cancer is a:
1) neoplastic transformation of glandular epithelium of the terminal duct unit, lactiferous proximal ducts, or lobules of the breast
2) almost always adenocarcinoma
3) classification is controversial, but most experts recognize in situ (malignant cells do not invade through the basement membrane) and invasive forms
4) in situ types – intraductal (comedo and noncomedo sutypes) in situ, lobular in situ, and papillary in situ
5) invasive types – ductal, lobular, tubular, colloid, and medullary
Signs and Symptoms
1) palpable mass – hard, irregular, no discr...
Source: Inside Surgery - March 21, 2013 Category: Surgeons Authors: Editor Tags: Breast Surgery Oncology adenocarcinoma BRCA1 BRCA2 comedo in situ invasive ductal Li Fraumeni lobular peau d'orange Source Type: blogs
David and Debbie Oliver's AAHPM Plenary: Comforting Others While Living
With Illness
One could write pages about David and Debbie Oliver's remarkable plenary presentation Friday at the American Academy of Hospice and Palliative Medicine Annual Assembly in New Orleans. David has stage IV nasopharyngeal carcinoma and has taken his cancer journey to the public. Before I go any further, I'll refer you to David's book, "Exit Strategy: Depriving Death of Its Strangeness," Paul Tatum's Interview with David at Geripal from August 2012, and below, see a clip from David's Cancer Videoblog in which he talks about cancer and palliative care.
Of the many themes which arose from their presentation, I was e...
Source: Pallimed: A Hospice and Palliative Medicine Blog - March 15, 2013 Category: Palliative Carer Workers Authors: Lyle Fettig, MD Source Type: blogs
Dr. Thomasina Bailey reviews pituitary session at recent USCAP meeting
A guest post from Thomasina Bailey, MD: I spent Saturday night, March 9, up late in Baltimore at the AANP session at USCAP. The talks focused on sellar lesions. The panel consisted of Drs. Lopez, Kleinschmidt-DeMasters, and Burger. Dr. Lopez from UVA gave a really great overview of sellar lesions focusing in on pituitary adenomas. She discussed the things that are clinically significant in the work-up of pituitary adenomas along with the controversies over atypical adenomas and carcinomas of the pituitary. At the end of her talk, she listed her own WHO classification of pituit...
Source: neuropathology blog - March 14, 2013 Category: Pathologists Tags: meetings Source Type: blogs
Nipple-Sparing Mastectomy
Nipple-sparing mastectomy in conjunction with immediate breast reconstruction is becoming more and more popular so I thought a blog post about it was in order...
What is a nipple-sparing mastectomy?
A nipple-sparing mastectomy preserves the nipple, areola and all the surrounding breast skin which is then used for the breast reconstruction. Unlike the traditional "modified radical mastectomy", nipple-sparing mastectomy only removes the breast tissue ("parenchyma") under the skin.
What are the benefits?
Studies show that nipple-sparing mastectomy provides the same level of surgical treatment as a modified radical ...
Source: Breast Cancer Reconstruction Blog - March 6, 2013 Category: Cancer Tags: nipple sparing mastectomy strong family history breast reconstruction cowden's syndrome modified radical mastectomy nipple-sparing nipple areola prophylactic mastectomy BRCA Source Type: blogs
Up And Down The Ladder… Job Changes
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone?
And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Curis hired Ali Fattaey as president and chief operating officer. Previous...
Source: Pharmalot - February 22, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized AcelRx Ariad Pharmaceuticals BioFocus Chimerix Curis Greenphire Gyros Lundbeck Protein Science Symphony Clinical Research Source Type: blogs
Only Some Mitochondrial DNA Damage Contributes to Aging
This research might be taken to illustrate the point that only some specific mutations in mitochondrial DNA (mtDNA) contribute to aging - those occurring in one of thirteen specific genes, per the SENS outline. So mice with accelerated mutation rates in all mitochondrial DNA exhibit accelerated aging, while mice with specific mitochondrial mutations that do not include those that contribute to aging do not exhibit accelerated aging.
It has been hypothesized that pathogenic mtDNA mutations that induce significant mitochondrial respiration defects cause mitochondrial diseases, and could also be involved in aging and age-ass...
Source: Fight Aging! - February 20, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, February 18th 2013
Discussion
- Latest Headlines from Fight Aging!
- Nitric Oxide and Longevity in Nematodes
- On Greater Longevity in Colder Environments
- Searching for Commonalities in Cancer
- Dietary Fatty Acids and Autophagy
- Comments on Teaching an Ethical View of Life Extension
- Arguing DNA Damage as a Cause of Aging
- Relative Risk For Causes of Cognitive Decline
- An Upcoming Oxford Debate With Aubrey de Grey and Richard Faragher
&nbs...
Source: Fight Aging! - February 17, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Newsletters Source Type: blogs
Searching for Commonalities in Cancer
The broad variety and rapid change in mechanisms within cancerous cells is one of the reasons that cancer is hard to tackle - every cancer is different and evolving. Circumventing this to find truly effective cancer therapies will require the discovery of some mechanistic commonality that can be targeted, some biological process that all cancers depend on and which distinguishes their cells from non-cancerous cells. The proposed SENS approach, for example, is to go right to the root and remove all ability to lengthen telomeres in the body, as all cancers depend on that. The mainstream research community aims to find marker...
Source: Fight Aging! - February 14, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Daily News Source Type: blogs
2012: Banner Year for New Drugs
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
As part of the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) promotes and protects the health of Americans by assuring that all prescription and over-the-counter drugs are safe and effective. The CDE...
Source: Highlight HEALTH - February 13, 2013 Category: Medical Scientists Authors: Walter Jessen, Ph.D. Source Type: blogs
Best Post of August 2012: A case of renal cell carcinoma metastatic to a meningioma
The next in our "Best of the Month" series is from August 9, 2012:A 74-year-old woman with a history of a seizure disorder had been followed for several years with a stable and unsymptomatic left parasagittal dural-based brain tumor presumed to be a benign meningioma. Recently, though, the lesion increased in size and hemorrhaged, leaving her significantly paretic on the right side. Neurosurgery thereupon performed a craniotomy for tumor removal. Intraoperative frozen section diagnosis was meningioma. But, upon receipt of the permanent sections, I was impressed by the staghorn vessels at low power and hemangioperic...
Source: neuropathology blog - January 25, 2013 Category: Pathologists Tags: neoplasms Best of the Month series Source Type: blogs
USMLE Questions – Characteristic Disease Findings
The United States Medical Licensing Examination (USMLE) is designed to emphasize knowledge of clinical scenarios and clinical pearls, even on Step I. Listed below are some commonly encountered disease findings and characteristics.
Feature
Disease
45, X chromosome
Turner’s syndrome
5-HIAA increased in urine
Carcinoid syndrome
Aganglionic rectum
Hirschsrpung’s disease
Apple-core sign on barium enema
Colon cancer
Arched back (opisthotonos)
Tetanus
Argyll-Robertson pupil
Syphilis
Ash leaf on forehead
Tuberous sclerosis
Auer rods
Acute myelogenous leukemia
Austin Flint murmur
Aortic regurgitation...
Source: Inside Surgery - January 18, 2013 Category: Surgeons Authors: Editor Tags: Surgpedia USMLE diseases findings VMA water hammer pulse Source Type: blogs
ENMD-2076 Monotherapy Demonstrates Anti-Cancer Activity in Recurrent, Platinum-Resistant Ovarian Clear Cell Carcinoma
An Aurora A/angiogenic kinase inhibitor named “ENMD-2076″ demonstrated anti-cancer activity in recurrent, platinum-resistant epithelial ovarian cancer patients, including three patients with a difficult-to-treat subtype of the disease referred to as “clear cell carcinoma.” An Aurora A/angiogenic kinase inhibitor named “ENMD-2076” demonstrated anti-cancer activity in recurrent, platinum-resistant epithelial ovarian cancer patients, including three patients with a [...] (Source: Libby's H*O*P*E*)
Source: Libby's H*O*P*E* - January 14, 2013 Category: Cancer Authors: Paul Cacciatore Tags: Clinical Trial Results Novel Therapies Pipeline Drugs Targeted Therapies angiogenic kinase inhibitor Aurora A kinase inhibitor Campbell Family Institute for Cancer Research clear cell carcinoma Dana-Farber Cancer Institute ENMD-2076 En Source Type: blogs
Video: Dr. Jack West discusses changing views on molecular testing in NSCLC
The Lungevity blog features a video of Dr. Jack West from Swedish Cancer Institute in Seattle discussing his evolving views regarding molecular testing for actionable driver mutations in non-small-cell lung cancer (NSCLC). Dr. West is a thought-leader in lung oncology... (Source: The Daily Sign-Out)
Source: The Daily Sign-Out - January 3, 2013 Category: Pathologists Authors: Mark D. Pool, M.D. Tags: Lung adenocarcinoma Lung Cancer Lung Squamous Cell Carcinoma Molecular Pathology Source Type: blogs
